Introduction
Despite the progress made in treating advanced nonsmall-cell lung cancer (NSCLC) [1] , responses to modern platinum-based chemotherapy are still infrequent and short-lived [2] [3] [4] . Because initial therapy rarely results in long-term tumor control, development of effective second-line treatments is an important component of a successful therapeutic strategy Docetaxel was the first drug to favorably impact on the natural history of chemotherapy-pretreated NSCLC [5] Modest but reproducible activity was initially noted in 4 phase II studies [6] [7] [8] [9] , resulting in an aggregate response rate of 17% (95% confidence interval (CI) 12%-23%) among 186 patients. In two subsequent randomized trials, docetaxel 75 mg/m 2 every three weeks resulted in survival benefit over vinorelbine-ifosfamide [10] , or best supportive care [11] . Docetaxel monotherapy of relapsed NSCLC has several limitations, however, including low response rates, brief durations of disease control, and minimal activity against tumors progressing during initial chemotherapy [10, 11] .
Gemcitabine is another modestly active drug against chemotherapy-pretreated NSCLC. The standard weekly x 3 gemcitabine schedule resulted in an aggregate response rate of 16% (95% CI: 12%-21%) among 254 patients [12] [13] [14] [15] [16] [17] , whereas the efficacy of abbreviated schedules in this setting is uncertain [18, 19] . Most gemcitabine responses have been obtained in patients with potentially chemosensitive disease, limited to nodal, or lung-to-lung metastatic sites [12, 13] . The distinct mechanisms of action, and demonstrable single-agent activity, support the rationale for adding gemcitabine to docetaxel in treating relapsed NSCLC. As compared to the two individual agents, the combination may result in superior antitumor activity, provided that clinically relevant drug doses can be given together in effective schedules.
In a previous phase I study, we demonstrated that gemcitabine 800 mg/m 2 administered on days 1, 8, and 15 could be safely combined with day 1 docetaxel 100 mg/m 2 , and observed encouraging antineoplastic activity consisting of partial responses in 9 of 21 patients with relapsed NSCLC [20] Based on the phase I experience, we conducted the present phase II study, to assess the efficacy and safety of monthly docetaxel, combined with weekly gemcitabine, in treating NSCLC patients after failure of one prior chemotherapy regimen.
Patients and methods

Eligibility
Patients with histologically confirmed NSCLC, failing only one prior chemotherapy regimen with no previous exposure to gemcitabine, or taxanes, were eligible All patients had bidimensionally measurable disease They also had adequate marrow, hepatic, and renal function, with an absolute neutrophil count (ANC) of 1500/ul or greater, platelet count of 100,000/ul or greater, total bihrubin level equal to the institutional upper limit of normal (ULN) or less, transaminase levels (ASTand ALT) 1 5-fold or less than ULN, alkaline phosphatase level 2 5-fold of ULN or less, peripheral neuropathy no worse than grade 2. serum creatinine level 2 0 mg/dl or less, and a Southwest Oncology Group performance status (PS) of 0-2 Patients with asymptomatic brain metastases were allowed to enroll, provided that they had additional disease sites and did not require immediate whole brain irradiation All patients were informed of the investigational nature of the study and written informed consent was obtained This phase II trial was approved by the Clinical Research Committee and Institutional Review Board of the Columbus Community Clinical Oncology Program (CCOP)
Presentment and follow-up evaluations
On study entry, all patients had a complete history and physical examination including dates, type, and response to first-line chemotherapy, performance status evaluation, complete blood cell counts with differentials, and serum chemistries performed. Imaging studies included computerized tomography (CT) scans of head, chest, and abdomen, and radionuchde bone scan Patients were evaluated weekly for toxicities Responses were assessed after completion of the second cycle of chemotherapy with CT scans of the measurable tumor sites, and confirmed after the fourth cycle of chemotherapy by imaging studies of all known and potential tumor sites Continuation of chemotherapy beyond the fourth cycle for responders and patients with stable disease was left to the discretion of the investigators
Treatment plan
Gemcitabine 800 mg/m 2 was administered as a 30-minute intravenous (i.v.) infusion, days 1,8, and 15, of a 28-day cycle Docetaxel 100 mg/m 2 was administered as a one-hour infusion after gemcitabine day 1 Both drugs were given in the outpatient setting, using five oral dexamethasone doses of 8 mg every 12 hours, starting 24 hours prior to docetaxel Neither colony-stimulating factors nor antiemetics were used prophylactically, but nlgrastim was recommended for patients who had in previous cycles experienced either febrile neutropenia, or grade 4 neutropenia lasting for seven or more days Within a cycle, the day 8 and day 15 doses of gemcitabine were reduced by 25% if. on the day of treatment, the ANC was 500-999/ul or the platelet count was 50,000-74.000/ul Gemcitabine was omitted for an ANC less than 500/ul and a platelet count less than 50,000/ul Docetaxel was omitted if. on the day of treatment, ANC was less than 1,500/ul or the platelet count was less than 75,0OO/ul. or the total bilirubin greater than ULN. or if the transaminases or alkaline phosphatase values were greater than 1 5-fold ULN and 2 5-fold ULN, respectively
The doses for both gemcitabine and docetaxel were permanently reduced by 25% if dose-limiting toxicities occurred in preceding cycles, including febrile neutropenia, grade 4 neutropenia lasting for seven or more days, platelet nadirs less than 20,000/ul, any grade 4 nonhemutologic toxicities, and grade 3 non-hematologic toxicities persisting for more than four weeks excepting asthenia
Response and toxicity criteria
Standard criteria were used for response assessments and all patients were considered as assessable for efficacy and toxicity Complete response (CR) was defined as resolution of all disease, for a minimum of eight weeks Partial response (PR) was defined as equal to, or greater than 50% reduction in the sum of the products of the longest perpendicular diameters of measurable lesions, and without appearance of new lesions, lasting at least eight weeks Progressive disease (PD) was defined as equal to, or greater than 25% increase in the sum of the products of perpendicular diameters of measurable lesions, or the appearance of new lesions Stable disease (SD) was designated for all patients not qualifying for CR, PR, or PD Toxicity was graded according to standard National Cancer Institute common toxicity criteria
Statistical methods
This phase II study was designed to detect a response rate of at least 20% A two-stage design was used, with initial enrollment of 20 patients, and subsequent accrual of 20 more patients if one or more responses were observed in the initial cohort [21] The regimen would be considered worthy of further study if eight or more confirmed responses were observed, provided that toxicity was acceptable Secondary end points were time to progression for responders, event-free, and overall survival Time to progression for responders was calculated from the date of treatment initiation to the date of documented relapse Event-free survival for all patients was calculated from the date of treatment initiation to the date of disease progression, or death Overall survival was calculated from the first day of treatment to the date of death, survival curves were estimated by the product-limit method [22] with log-rank comparisons Received dose intensities were calculated by the method of Hryniuket al [23] 
Results
Patient characteristics
Between October 1997 and October 1999, 40 patients with advanced chemotherapy-pretreated NSCLC were enrolled onto this study at five Central Ohio sites, with data collected and compiled by staff of the Columbus Community Clinical Oncology Program. Data analysis is current as of February 2000. Characteristics of patients and their tumors are summarized in Table 1 . The median age was 62 years, and adenocarcinoma was the most common histology Twelve patients (30%) had a performance status of 2, and eighteen patients (45%) had documented significant weight loss. Metastatic disease was present in 80% of patients. Prior chemotherapy was platinum-based in 90% of patients, combined with vinorelbine in 65%, and etoposide in 25%. Most patients (80%) had tumors that were either refractory, or resistant to first-line chemotherapy as defined in Table 2 Dose delivery A total of 133 cycles were delivered, with a median of three cycles per patient (range, less than one to eight cycles) Only five cycles were delayed for a week or longer, due to patient request in four cases, and flu-like Renal, muscle, spleen b Vinorelbine (two patients), oral etoposide, and fluorouracil-leucovorin (one patient each) c Because initial chemotherapy was given in the adjuvant setting symptoms in one case. The mean delivered gemcitabine dose intensity was 441 mg/m 2 /week (74% of planned), and the mean delivered docetaxel dose intensity was 23.8 mg/m 2 /week (95% of planned). Intracycle dose delivery of gemcitabine is shown in Table 3 . Day 8 gemcitabine dose reductions or omissions were for neutropenia (80%), thrombocytopenia (3%), or both (7%), and physician or patient choice (10%); reasons for dose-reducing or omitting day 15 gemcitabine were neutropenia (62%), thrombocytopenia (15%), or both (12%), and patient request or physician preference (11%) Despite dose omissions, all three weekly gemcitabine doses could be given in 61% ofcycles. Permanent dose reductions for docetaxel and gemcitabine were necessary in nine patients due to febrile neutropenia (four), prolonged grade 4 neutropenia (two), severe asthenia (two), and severe thrombocytopenia (one).
Toxicities
Toxicities observed during 133 cycles of chemotherapy are summarized in Table 4 . The principal hematological toxicity was neutropenia. Although ANC nadirs less than 500/ul were observed in 27% of all chemotherapy cycles, only 4 of 133 cycles were complicated by febrile neutropenia. These four patients recovered uneventfully after treatment with l v. antibiotics and suffered no further febrile neutropenic episodes during subsequent chemotherapy cycles Two additional patients had uncomplicated grade 4 neutropenia lasting longer than seven days. Filgrastim was given to six patients. Anemia was common, with 9 patients receiving a total of 20 units of packed red blood cells. Grade 1-2 thrombocytopenia was observed in 38% of cycles, affecting 18 patients, whereas grade 3-4 thrombocytopenia was noted in 12% of cycles, affecting 9 patients. Four patients required platelet transfusions, receiving a total of sixteen platelet units, but there were no clinically significant bleeding complications The majority of patients experienced periods of moderate to severe asthenia. The severity of asthenia remained stable or improved during successive cycles of chemotherapy in 18 patients, whereas 9 individuals experienced worsening cumulative asthenia. Overall, severe fatigue led to permanent dose reductions in two patients, and necessitated treatment discontinuation in three patients.
Fluid retention, appearing after a median of three cycles, was mainly manifested as pedal edema responsive to thiazides and loop diuretics. One patient developed a symptomatic non-malignant pleural effusion that required therapeutic thoracentesis. Despite the lack of routine antiemetic premedication, severe nausea and emesis were infrequent. Flu-like symptoms of chills, rigors, fevers, malaise, arthralgias and myalgias affected 32% of the patients and were severe in 5%. These symptoms occurred within 24-^18 hours after the gemcitabine infusions and their severity could be ameliorated during subsequent courses with diphenhydramine and hydrocortisone given prior to gemcitabine.
Other side effects were well tolerated. Nail toxicity with ridging and dark discoloration was common. Grade 3 hepatic dysfunction, seen in one patient, consisted of transient asymptomatic transaminase elevation. Skin toxicity was mild and consisted of maculopapular erythematous eruptions in eight patients. For most patients, sensory neuropathy was mild and non-progressive, with only two episodes of reversible grade 3 neuropathy occurring in patients with pre-existing chemotherapyinduced sensory damage. In addition to the toxicities mentioned in Table 4 , five patients experienced abdominal pains, and two patients experienced mild infusion reactions to docetaxel that resolved by slowing the drug infusion rate
Efficacy
The overall response rate in 40 patients, analyzed on an intent-to-treat basis, was 32.5% (13 of 40; 95% CI: 19%-49%). There were 1 complete and 12 partial confirmed responses. Responding organ sites included the lung primary and lung-to-lung metastases (12 patients), lymph nodes (3), lytic bone metastases (3), hepatic metastases (2), and adrenal, renal, subcutaneous, and brain metastases (one each). Responses were seen in 2 of 6 chemosensitive, 7 of 18 resistant, and 4 of 14 refractory tumors Two of twelve PS 2 patients and eleven of twety-eight PS 0-1 patients responded There were 2 responses among 0 2 4 6 8 10 12 14 16 18 20 22 24 0.00 Figure 1 Overall survival from start of treatment 13 patients with squamous histologies and 11 responses among 27 patients with non-squamous histologies, including 2 responders with bronchioalveolar carcinoma.
The median event-free survival for all patients was 4.4 months (range 0.3-19.3 months). For the 13 responders, the median time to disease progression measured from study entry was 9 months (range 5.8-19.3 months). Two responding patients who entered the study with hepatic and skeletal metastases resistant to cisplatin-vinorelbine remained progression-free for more than a year (19.3 and 17+ months).
With a median potential follow-up period of 15.9 months, the median survival duration for all 40 patients was 8 1 months (range 0.3-21.4+ months). The actuarial 12-month survival probability is 32% (Figure 1 ). With limited statistical power due to small subgroup numbers, survival was not affected by sex, disease stage, or significant pretreatment weight loss. Patients with performance status of 0-1 survived longer than patients with performance status of 2 (median survival 10.5 months vs. 2.5 months; log-rank, P = 0.0015), with 12-month actuarial survival rates of 46% vs. 0%. Ten patients eventually received third-line chemotherapy treatments with docetaxel (five), docetaxel plus gemcitabine (two), and with gemcitabine, vinorelbine, and multiple regimens in one patient each
Discussion
The modest but consistent activity of docetaxel and gemcitabine in patients with chemotherapy-pretreated NSCLC prompted the development of this doublet As compared to monotherapy with docetaxel or gemcitabine, concurrent delivery of both drugs may enhance antineoplastic activity, and, on the basis of their distinct intracellular targets, it may overcome resistance to platinum compounds. To maximize second-line efficacy, a monthly docetaxel schedule aiming to deliver optimal [10, 11] docetaxel dose intensity (25 mg/m 2 /week) was combined with an active [12] [13] [14] [15] [16] weekly gemcitabine schedule Because gemcitabine doses as low as 350 mg/m 2 infused over 30 minutes are sufficient for maximal cellular formation of the active metabolite dFdCTP [24, 25] , a major detrimental impact of intracycle gemcitabine dose reductions on antitumor efficacy was considered unlikely. Therefore, the routine use of growth factors to maintain gemcitabine dose intensity was not deemed necessary.
Dose delivery and efficacy outcomes appear to validate these concepts The great majority of treatment courses were given at full docetaxel doses, with only 15% of patients receiving filgrastim. The weekly x 3 gemcitabine schedule was maintained in the majority of cycles, and delivery of potentially active gemcitabine doses exceeding 350 mg/m 2 was feasible in 74% and 82% of cycles on days 8 and 15, respectively. The resulting intent-to-treat response rate of 32.5% represents an approximate doubling of previously reported response rates with gemcitabine or docetaxel alone, and compares favorably to the activity of other taxane combinations with abbreviated gemcitabine schedules in chemotherapypretreated NSCLC [26, 27] . The observed responses in tumors resistant or refractory to initial chemotherapy indicate incomplete cross-resistance to platinum combinations with vinorelbine or etoposide Arguably, this response rate could be partially attributed to confounding effects resulting from residual tumor sensitivity to chemotherapy, lack of prior exposure to paclitaxel, and response assessment variability common to all phase II studies. It should be noted, however, that prospectively defined refractory or resistant disease was predominant, prior paclitaxel therapy has not been shown to compromise subsequent docetaxel activity [10] , and durable responses were observed in a variety of metastatic sites.
Compared to docetaxel alone [6, 8] , the addition of gemcitabine did not appear to enhance the frequency of severe neutropenia With infectious complications being infrequent, readily manageable, and always preventable during subsequent cycles of chemotherapy, neutropenia remained for most patients a clinically irrelevant laboratory observation. In this patient group, the frequency of thrombocytopenia was higher than previously observed with gemcitabine alone [12, 13] , yet it did not result in bleeding sequelae. The concurrent administration of the two drugs also exacerbated asthenia, whereas there was no increase in the incidence and severity of other nonhematological toxicities, including fluid retention, cutaneous toxicity, and elevated liver enzymes.
Survival was a secondary end-point in this phase II trial. It is recognized that NSCLC patients receiving second-line chemotherapy comprise a highly heterogenous population in terms of tumor characteristics, sensitivity to prior chemotherapy, and performance status. Even the process of entering a second-line clinical trial may select for indolent tumor behavior and biological resilience, as individuals suffering treatment-related or tumor-related rapid deterioration in organ function and performance status will not fulfil enrollment criteria. Therefore, it is uncertain whether the observed survival resulted from beneficial treatment effects, or from favorable baseline patient characteristics. Similar to the experience in chemotherapy-naive NSCLC populations [28, 29] , performance status was the major survival determinant in the present second-line study Despite having a higher proportion of poor performance patients, the median survival of 8.1 months compares favorably to median survivals of 5.7-7 months noted in recent docetaxel monotherapy studies [8, 10, 11] . However, such non-randomized comparisons serve only as hypotheses to be further tested in randomized trials.
Are the results obtained with this combination sufficient to warrant more frequent asthenia and uncomplicated thrombocytopenia over single-agent gemcitabine or docetaxel? Pending a formal randomized comparison of survival and quality of life, these reversible and nonhfe-threatening toxicities may be a reasonable trade-off for attaining a higher rate of durable responses and favorable survival, especially in good performance patients.
In summary, monthly docetaxel combined with weekly gemcitabine is an active and safe second-line NSCLC doublet, resulting in a substantial proportion of good quality responses, irrespective of tumor sensitivity to prior chemotherapy. Excepting asthenia and transient asymptomatic thrombocytopenia, these responses were obtained without an appreciable increase in the burden of toxicities over the use of each drug alone. Studies are in progress to determine whether earlier introduction of this doublet will improve prognosis in chemotherapynaive NSCLC patients 
